More than 35,000 physicians, allied healthcare providers and industry representatives descended on the cavernous convention center in Boston’s up-and-coming Seaport section for the Heart Rhythm Society’s annual meeting.
Cameron Health Inc.
MassDevice.com +7 | The top 7 med-tech stories for the week of May 7, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
HRS 2012: Is Cameron Health’s ‘leadless’ ICD a niche product or a game-changer?
The so-called "leadless" implantable cardiac defibrillator made by Cameron Health made its debut at the Heart Rhythm Society’s annual meeting this week, generating considerable excitement among physicians here in Boston.
Two studies presented at the conference, 1 sponsored by Cameron Health to back its investigational device exemption application with the FDA and a 2nd, "real-world" evaluation of European patients, both showed that the subcutaneous ICD has comparable safety and effectiveness rates as more traditional transvenous ICDs.
HRS 2012 UPDATE: Riata’s survival rate ‘significantly worse’
A study comparing recalled defibrillator leads made by St. Jude Medical (NYSE:STJ) with 1 from rival Medtronic (NYSE:MDT) found 1 St. Jude model’s survival rate to be "significantly worse."
BSX ticks up on positive panel vote for Cameron S-ICD
Another heart device won a nod from an FDA advisory panel yesterday when Cameron Health’s subcutaneous implantable cardiac defibrillator won rave reviews from the committee, sending Boston Scientific (NYSE:BSX) shares up a tick today on Wall Street
MassDevice.com +3 | The top 3 med-tech stories for April 24, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Analysts cautious on Boston Scientific’s $1.3B lead-free ICD ahead of FDA panel
Study results released ahead of an FDA panel review for Boston Scientific (NYSE:BSX) subsidiary Cameron Health’s lead-free subcutaneous implantable cardioverter defibrillator has some Wall Street analysts wondering whether a substantial market exists for the devices.
HRS preview: St. Jude, Boston Scientific in the spotlight | Wall Street Beat
The foofaraw over St. Jude Medical‘s (NYSE:STJ) recalled Riata defibrillator leads is slated for top billing at the upcoming annual meeting of the Heart Rhythm Society in Boston, according to a pair of Leerink Swann analysts.
MassDevice.com +3 | The top 3 med-tech stories for March 19, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Cameron Health’s FDA date is good news for Boston Scientific
Cameron Health landed an April date with the FDA’s circulatory devices panel to review a pre-market approval application for its lead-free subcutaneous implantable cardioverter defibrillator, or S-ICD.
The S-ICD system, unlike traditional ICDs, sits just beneath the skin and does not rely on wires relayed through blood vessels and connected to the heart in order to provide heart rhythm therapy.
Report: Covidien to acquire superDimension for $350M | Wall Street Beat
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.